In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats

Journal of Veterinary Internal Medicine

Volumn 22, Issue 1, 2008, Pages 158-163

  Wypij, J M ^a   Fan, T M ^a,b   Fredrickson, R L ^b   Barger, A M ^b   De Lorimier, L P ^a   Charney, S C ^a  

^a Department of Veterinary Clinical Medicine ^*

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Aminobisphosphonate; Cancer; Focal malignant osteolysis; Serum C telopeptide; Soluble vascular endothelial growth factor

Indexed keywords

ANIMALIA; FELIDAE;

EID: 40549130382     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2007.0010.x     Document Type: Article

References (40)

1. 1 Klein MK. Multimodality therapy for head and neck cancer. Vet Clin North Am Small Anim Pract 2003 ; 33: 615–628.
2. 2 Quigley PJ, Leedale AH. Tumors involving bone in the domestic cat: A review of fifty-eight cases. Vet Pathol 1983 ; 20: 670–686.
3. 3 Stebbins KE, Morse CC, Goldschmidt MH. Cat oral neoplasia: A ten-year survey. Vet Pathol 1989 ; 26: 121–128.
4. 4 Hutson CA, Willauer CC, Walder EJ, et al. Treatment of mandibular squamous cell carcinoma in cats by use of mandibulectomy and radiotherapy: Seven cases (1987–1989). J Am Vet Med Assoc 1992 ; 201: 777–781.
5. 5 Northrup NC, Selting KA, Rassnick KM, et al. Outcomes of cats with oral tumors treated with mandibulectomy: 42 cases. J Am Anim Hosp Assoc 2006 ; 42: 350–360.
6. 6 Ogilvie GK, Moore AS, Obradovich JE, et al. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. J Am Vet Med Assoc 1993 ; 202: 1839–1844.
7. 7 Mauldin GN, Matus RE, Patnaik AK, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988 ; 2: 60–65.
8. 8 Fox LE, Rosenthal RC, King RR, et al. Use of cis‐bis‐neodecanoato‐trans‐ R,R ‐1,2‐diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. Am J Vet Res 2000 ; 61: 791–795.
9. 9 Bregazzi VS, LaRue SM, Powers BE, et al. Response of cat oral squamous cell carcinoma to palliative radiation therapy. Vet Radiol Ultrasound 2001 ; 42: 77–79.
10. 10 Jones PD, De Lorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable cat oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003 ; 39: 463–467.
11. 11 Evans SM, LaCreta F, Helfand S, et al. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous cat oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1991 ; 20: 703–708.
12. 12 LeBlanc AK, LaDue TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004 ; 45: 466–470.
13. 13 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100: 57–70.
14. 14 Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002 ; 29: 15–18.
15. 15 Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001 ; 114: 853–865.
16. 16 Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004 ; 117: 3–32.
17. 17 Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005 ; 6: 1701–1711.
18. 18 Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006 ; 11: 1121–1131.
19. 19 Good CR, O'Keefe RJ, Puzas JE, et al. Immunohistochemical study of receptor activator of nuclear factor kappa‐B ligand (RANK‐L) in human osteolytic bone tumors. J Surg Oncol 2002 ; 79: 174–179.
20. 20 Huang L, Cheng YY, Chow LT, et al. Tumour cells produce receptor activator of NF‐kappaB ligand (RANKL) in skeletal metastases. J Clin Pathol 2002 ; 55: 877–878.
21. 21 Lipton A, Berenson JR, Body JJ, et al. Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference. Clin Cancer Res 2006 ; 12: 6209s–6212s.
22. 22 Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone‐stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 ; 62: 6538–6544.
23. 23 Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003 ; 9: 295–306.
24. 24 Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004 ; 10: 4559–4567.
25. 25 Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM‐bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003 ; 18: 482–492.
26. 26 Giraudo E, Inoue M, Hanahan D. An amino‐bisphosphonate targets MMP‐9‐expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004 ; 114: 623–633.
27. 27 Tannehill‐Gregg S, Levine A, Rosol T. Cat head and neck squamous cell carcinoma: A natural model for the human disease and development of a mouse model. Vet Comp Oncol 2006 ; 4: 84–97.
28. 28 Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long‐lasting modifications of circulating angiogenic factors in cancer cats. Clin Cancer Res 2003 ; 9: 2893–2897.
29. 29 Saad F. Bisphosphonates in prostate cancer: Where are we and where should we go? J Natl Cancer Inst 2003 ; 95: 1262–1263.
30. 30 Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid‐related angiogenesis modifications and survival in advanced breast cancer cats. J Interferon Cytokine Res 2005 ; 25: 144–151.
31. 31 Ferretti G, Fabi A, Carlini P, et al. Zoledronic‐acid‐induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer cats. Oncology 2005 ; 69: 35–43.
32. 32 Barger AM, Fan TM, De Lorimier LP, et al. Expression of receptor activator of nuclear factor kappa‐B ligand (RANKL) in neoplasms of dogs and cats. J Vet Intern Med 2007 ; 21: 133–140.
33. 33 Koga L, Kobayashi Y, Yazawa M, et al. Nucleotide sequence and expression of the cat vascular endothelial growth factor. J Vet Med Sci 2002 ; 64: 453–456.
34. 34 DeLaurier A, Jackson B, Pfeiffer D, et al. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats. Res Vet Sci 2004 ; 77: 29–39.
35. 35 De Lorimier LP, Fan TM. Bone metabolic effects of single‐dose zoledronate in healthy dogs. J Vet Intern Med 2005 ; 19: 924–927.
36. 36 Hamma‐Kourbali Y, Di Benedetto M, Ledoux D, et al. A novel non‐containing‐nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 2003 ; 310: 816–823.
37. 37 Demers LM. Bone markers in the management of cats with skeletal metastases. Cancer 2003 ; 97: 874–879.
38. 38 Lacoste H, Fan TM, De Lorimier LP, et al. Urine N‐telopeptide excretion in dogs with appendicular osteosarcoma. J Vet Intern Med 2006 ; 20: 335–341.
39. 39 Rusk A, McKeegan E, Haviv F, et al. Preclinical evaluation of antiangiogenic thrombospondin‐1 peptide mimetics, ABT‐526 and ABT‐510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006 ; 12: 7444–7455.
40. 40 Migliorati CA, Siegel MA, Elting LS. Bisphosphonate‐associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 2006 ; 7: 508–514.